Home Cart Sign in  
Chemical Structure| 361185-42-4 Chemical Structure| 361185-42-4

Structure of RBC8
CAS No.: 361185-42-4

Chemical Structure| 361185-42-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

RBC8 is an inhibitor of GTPases RalA and RalB with IC50 of 3.5 μM in cell assay.

Synonyms: RBC8

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of RBC8

CAS No. :361185-42-4
Formula : C25H20N4O3
M.W : 424.45
SMILES Code : N#CC(C1C2=CC(OC)=CC=C2OC)=C(N)OC3=C1C(C4=CC=C5C=CC=CC5=C4)=NN3
Synonyms :
RBC8
MDL No. :N/A
InChI Key :CLMQBVUFKIKYLU-UHFFFAOYSA-N
Pubchem ID :6626226

Safety of RBC8

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Related Pathways of RBC8

GPCR

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Human platelets 2.2 μM (RalA), 2.3 μM (RalB) 15 minutes RBC8 effectively inhibited Ral GTPase activation, significantly inhibiting platelet aggregation, secretion (α- and dense granules), integrin activation, and thrombus formation Cell Signal. 2019 Jul;59:34-40.
MDA-MB-453 27.71 μM 5 days Evaluate cytotoxicity of RBC8 on HER2+ cell line MDA-MB-453 Cancers (Basel). 2024 Aug 31;16(17):3043.
SKBR3 25.72 μM 5 days Evaluate cytotoxicity of RBC8 on HER2+ cell line SKBR3 Cancers (Basel). 2024 Aug 31;16(17):3043.
BT-474 28.70 μM 5 days Evaluate cytotoxicity of RBC8 on HER2+ cell line BT-474 Cancers (Basel). 2024 Aug 31;16(17):3043.
MDA-MB-468 60.30 μM 5 days Evaluate cytotoxicity of RBC8 on TNBC cell line MDA-MB-468 Cancers (Basel). 2024 Aug 31;16(17):3043.
BT-549 43.14 μM 5 days Evaluate cytotoxicity of RBC8 on TNBC cell line BT-549 Cancers (Basel). 2024 Aug 31;16(17):3043.
MDA-MB-231 53.34 μM 5 days Evaluate cytotoxicity of RBC8 on TNBC cell line MDA-MB-231 Cancers (Basel). 2024 Aug 31;16(17):3043.
BaF3-P210 cells 1–5 μM 48 hours RBC8 enhances the inhibitory effects of imatinib in BaF3-P210 cells. Oncotarget. 2016 Apr 12;7(15):20561-73.
KCL-22 cells 3 μM 48 hours RBC8 significantly reduced RalA GTPase activity in KCL-22 cells. Oncotarget. 2016 Apr 12;7(15):20561-73.
K562 cells 1–5 μM 48 hours RBC8 effectively inhibited K562 cell viability, and overexpression of RalA could produce some resistance to RBC8. Oncotarget. 2016 Apr 12;7(15):20561-73.
Mouse platelets 1-10 μM 15 minutes RBC8 showed dose-dependent inhibition of integrin activation and dense granule secretion in RalAB-null mouse platelets, with significant inhibition of platelet aggregation and P-selectin exposure at 10 μM Cell Signal. 2019 Jul;59:34-40.
MGC-803 cells 20 µM and 40 µM RBC8 significantly inhibited cell growth, migration, and invasion of MGC-803 cells in a dose-dependent manner. Onco Targets Ther. 2020 Apr 14;13:3093-3103.
SGC-7901 cells 20 µM and 40 µM RBC8 significantly inhibited cell growth, migration, and invasion of SGC-7901 cells in a dose-dependent manner. Onco Targets Ther. 2020 Apr 14;13:3093-3103.

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.36mL

0.47mL

0.24mL

11.78mL

2.36mL

1.18mL

23.56mL

4.71mL

2.36mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories